Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Upadacitinib shows promising results in ongoing phase 3 atopic dermatitis studies

By Brian Buntz | October 11, 2023

AbbVie logoAbbVie has shared new efficacy and safety data for Rinvoq (upadacitinib) in adults and adolescents with atopic dermatitis (AD) from a trio of ongoing phase 3 studies. Spanning 140 weeks, these studies sustained the co-primary endpoints of Eczema Area and Severity Index 75 (EASI 75) and validated Investigator’s Global Assessment for Atopic Dermatitis 0/1 (vIGA-AD 0/1), both important measures of skin clearance and itch reduction. AD is a prevalent inflammatory skin condition, affecting roughly one in ten adults and about one-quarter of adolescents.

The company shared the data at the 32nd European Academy of Dermatology and Venereology (EADV) Congress in Berlin.

Efficacy of upadacitinib in Measure Up 1, Measure Up 2, and AD Up

The trials indicated a substantial number of patients on upadacitinib (administered in either 15 mg or 30 mg doses) achieving the set primary efficacy endpoints by the 16th week in the Measure Up 1, Measure Up 2, and AD Up phase 3 studies. Not only did patients on upadacitinib fare better than those on placebo in achieving the primary efficacy endpoints at four weeks, but they also had significant improvements in secondary measures. The JAK1 inhibitor was particularly effective in achieving high Eczema Area and Severity Index scores (EASI 90) and in providing relief from severe itching (WP-NRS 0/1). This efficacy profile remained steady throughout the duration of the 140-week studies.

“Previous analyses from the phase 3 Rinvoq studies showed major improvements in quality of life with both the 15 and 30 mg doses of Rinvoq,” said Dr. Jonathan Silverberg, lead study investigator and director of clinical research, George Washington University School of Medicine and Health Science. “The analyses just presented at EADV particularly examined the long-term efficacy of Rinvoq on skin clearance and itch reduction out to 140 weeks of treatment. The results showed continued high-level improvements in both skin clearance and itch reduction for both the 15 and 30 mg doses of Rinvoq.”

The bar graph below illustrates the percentage of patients who met specific endpoints in the Measure Up 1, Measure Up 2, and AD Up studies at week 140 for different doses. These endpoints encompass the Eczema Area and Severity Index 75 (EASI 75), the validated Investigator’s Global Assessment for Atopic Dermatitis 0/1 (vIGA-AD 0/1), the Eczema Area and Severity Index 90 (EASI 90), and the Worst Pruritus Numeric Rating Scale (WP-NRS) scores.

Safety profile in the phase 3 studies

The long-term extension of the three pivotal studies cemented the consistent safety profile of upadacitinib, with both the 15 mg and 30 mg doses well-tolerated. Clinical investigators found no new safety signals. Treatment-emergent adverse events were in line with previously observed outcomes and no significant discrepancies emerged in the treatment groups. Additionally, rates of adverse events of special interest were similar across treatment groups.

Upadacitinib’s multifaceted efficacy

A number of recent post-hoc analyses from the atopic dermatitis trials have “provided important insights into the efficacy of Rinvoq in AD,” Silverberg said.

Silverberg noted that studies are underway to that are scrutinizing the comparative efficacy of different dosing strategies for Rinvoq in AD. “Also, while updacitinib is currently approved for seven indications, including atopic dermatitis, it is also being studied in other immune-mediated diseases,” he added.

Regulatory milestones for upadacitinib

Upadacitinib won FDA approval for individuals with moderate to severe atopic dermatitis at least 12 years old in early 2022. The approval covered individuals whose dermatitis hasn’t responded to previous treatments or for whom other dermatitis therapies are not recommended. At that time, AbbVie projected upadacitinib’s risk-adjusted sales to surpass $7.5 billion by 2025. In 2022, the drug, together with the monoclonal antibody Skyrizi (risankizumab-rzaa), generated almost $7.7 billion of combined sales in 2022.

In August 2019, the FDA granted its first approval to upadacitinib as an oral JAK inhibitor for moderate to severe rheumatoid arthritis. By December 2021, the drug received further approvals for active psoriatic arthritis. In March 2022, it won approval for treating adults with moderately to severely active ulcerative colitis, followed by approval for active ankylosing spondylitis in April 2022. Later that year, in October 2022, the FDA extended the drug’s indication to adults with active non-radiographic axial spondyloarthritis. Most recently, in May 2023, the FDA greenlighted upadacitinib as a once-daily oral pill for moderately to severely active Crohn’s disease in adults.


Filed Under: clinical trials, Dermatology, Drug Discovery, Immunology, Regulatory affairs
Tagged With: AbbVie, atopic dermatitis, EADV, EADV Congress, Eczema Area and Severity Index, European Academy of Dermatology and Venereology, Investigator's Global Assessment, JAK1 inhibitor, Phase 3 Studies, Rinvoq, upadacitinib
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Takeda
TAK-279, an oral small-molecule TYK2 inhibitor offering the convenience of a once-daily pill and biologic-like clinical responses
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE